Free press releases distribution network?

Agency / Source: STEMCELL Technologies, Inc.

Check Ads Availability|e-mail Article
This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



STEMCELL Technologies Signs Exclusive License to Commercialize Human Pluripotent Stem Cell-Derived Kidney Organoid Culture System - STEMCELL Technologies announced that they have signed an exclusive license agreement with Brigham and Women’s Hospital for rights to commercialize technologies for the generation of human pluripotent stem cell-derived kidney organoids - Stemcell.com
STEMCELL Technologies Signs Exclusive License to Commercialize Human Pluripotent Stem Cell-Derived Kidney Organoid Culture System

 

PRTODAY - Newswire & PRZOOM/ - Vancouver, British Columbia, Canada, 09/25/2018 - STEMCELL Technologies announced that they have signed an exclusive license agreement with Brigham and Women’s Hospital for rights to commercialize technologies for the generation of human pluripotent stem cell-derived kidney organoids - Stemcell.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

STEMCELL Technologies has today announced that they have signed an exclusive license agreement with Brigham and Women’s Hospital for rights to commercialize technologies for the generation of human pluripotent stem cell-derived kidney organoids.

This innovative technology, developed by Drs. Benjamin S. Freedman when he was at Brigham and Women’s Hospital and Joseph V. Bonventre (Chief of the Division of Renal Medicine and Chief of the Engineering in Medicine Division at Brigham and Women’s Hospital), enables the growth of organoids, or mini-organs, that recapitulate key characteristics of renal development and physiology in vitro. These organoids provide a reproducible and versatile framework for modeling renal physiology, injury and disease at distinct developmental stages.

Dr. Freedman, currently an Assistant Professor, Medicine/Nephrology at the University of Washington Institute for Stem Cell & Regenerative Medicine stated that "organoids are powerful research tools, but currently require specialized knowledge and skills to implement. Establishing a standardized kit for kidney organoid differentiation will make it much easier for many laboratories to adopt this exciting new technology. This will accelerate the pace of organoid research and enable it to reach its full potential for biomedicine. As an inventor, I am especially pleased that this standardization effort is being led by STEMCELL, which is a world-renowned leader in providing high-quality, cutting-edge products to the stem cell research community.”

Dr. Allen Eaves, STEMCELL’s President and CEO, commented that “STEMCELL is thrilled to commercialize such an exciting and vital technology. This partnership will enable us to provide a robust 3D culture to facilitate kidney research and the development of regenerative medicine in the field.”

About STEMCELL Technologies

As Scientists Helping Scientists™, STEMCELL Technologies (stemcell.com) is committed to providing high-quality cell culture media, cell isolation products, accessory reagents and services for life science research. Driven by science and a passion for quality, STEMCELL Technologies offers over 2500 products designed to support the basic to translational research continuum.

Masako Adachi, Senior Business Development Officer STEMCELL Technologies
E: masako.adachi[.]stemcell.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: STEMCELL Technologies, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRTODAY - Newswire Distribution Service Visibility Checker

 

Distribution / Indexing: [+] [Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


STEMCELL Technologies Signs Exclusive License to Commercialize Human Pluripotent Stem Cell-Derived Kidney Organoid Culture System

Non-featured company website links are shown on a random basis
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRTODAY - Newswire Distribution Service and LINK as the source.
 
  For more information, please visit:
Links are available on a random basis for non premium members
Human Pluripotent Cell | STEMCELL Technologies, In
Contact: Press Office - Stemcell.com 
604-877-0713 marketing[.]stemcell.com
 
Newswire Today - PRZOOM disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.

Pharma/BioTech/Nutrition via RSS
AddThis press release: STEMCELL Technologies Signs Exclusive License to Commercialize Human Pluripotent Stem Cell-Derived Kidney Organoid Culture SystemAdd Pharma/BioTech/Nutrition News to My MSNAdd Pharma/BioTech/Nutrition News to My Yahoo!Add NewswireToday Pharma/BioTech/Nutrition Press Release Headline News to Your Google homepage or Google ReaderAdd NewswireToday - PRZOOM Headline News to FeedBurner

This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read More Articles From STEMCELL Technologies, Inc. / Company Profile



Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Sartorius Stedim Biotech Introduces BIOSTAT® RM TX with Flexsafe® RM TX for Producing Consistent Quality Cellular Products
Sartorius to Demonstrate Special Data Analysis At Night of Knowledge Event Series
FDA Accepts Genentech’s Supplemental Biologics License Application for Tecentriq Plus Chemotherapy (Abraxane and Carboplatin)
Cell Therapy Market to Grow Beyond Oncology As Big Pharma Expands Investments Finds Frost & Sullivan
Bioquark, Inc. and Ectocrine Technologies, LLC to Collaborate on Mosquito-Derived Health Products
BTG and OMNY Partner to Improve Treatment of Snake Bite Victims
FDA Approves Genentech’s Tecentriq in Combination with Avastin and Chemotherapy
Exelixis and Ipsen Initiate Phase 3 Pivotal Trial of Cabozantinib in Combination with Atezolizumab Versus Sorafenib
Ipsen and 3BP Announce First Patient Dosed in Phase I/II study for First-in-Class Radionuclide (IPN01087)
EC Approves Ipsen’s Cabometyx® (cabozantinib) for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib

Reserve This Permanent SPACE

Your LOGO permanently HERE on PRTODAY - Newswire Distribution Service most visited Page start at $295 per month

 
Sponsored Links


Visit  BizJobs.com

Visit  RightITnow, Inc.

Visit  JobsWare.com





Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



 
  ©2014 PRTODAY — Limelon Advertising, Co.
Home | About PRTODAY | Advertise | Contact | Investors | Sitemap | FRANCAIS
newswire, PR free press releases distribution magazines engine news alert newsroom press room breaking news public relations articles company news alerts blogsIt younews.me newswiredistribution ezine younews.asia bizentrepreneur biznewstoday digital business report news market search pr firms pr agencies business reports newswire today distri- bution investor relation successful internet entrepreneur free newswire distribution prtoday freenewswiredistribution.com asianewstoday bizwiretoday newswire pr today
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)